Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke
Stephan Windecker, MD*,*,
Andreas Wahl, MD*,
Krassen Nedeltchev, MD ,
Marcel Arnold, MD ,
Markus Schwerzmann, MD*,
Christian Seiler, MD, FACC*,
Heinrich P. Mattle, MD and
Bernhard Meier, MD, FACC*,*
* Cardiology
Neurology, University Hospital, Bern,Switzerland

View larger version (18K):
[in a new window]
|
Figure 1 Probability of death, recurrent stroke, or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line).
|
|

View larger version (18K):
[in a new window]
|
Figure 2 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line).
|
|

View larger version (19K):
[in a new window]
|
Figure 3 Risk ratios according to treatment assignment in subgroups. PFO = patent foramen ovale; ASA = atrial septal aneurysm.
|
|

View larger version (20K):
[in a new window]
|
Figure 4 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line) in the subgroup of patients with complete PFO occlusion.
|
|

View larger version (19K):
[in a new window]
|
Figure 5 Probability of recurrent stroke or transient ischemic attack stratified for medical treatment (continuous line) and percutaneous patent foramen ovale (PFO) closure (dashed line) in the subgroup of patients with more than one cerebrovascular event at baseline.
|
|
|